"March 7, 2013 -- An FDA panel voted to stop recommending calcitonin salmon for the treatment of osteoporosis in women who are at least five years past menopause.
The committee voted 12-9 against continued marketing of the drug, citing"...
Skelid Patient Information including How Should I Take
In this Article
- What is tiludronate (Skelid)?
- What are the possible side effects of tiludronate (Skelid)?
- What is the most important information I should know about tiludronate (Skelid)?
- What should I discuss with my healthcare provider before taking tiludronate (Skelid)?
- How should I take tiludronate (Skelid)?
- What happens if I miss a dose (Skelid)?
- What happens if I overdose (Skelid)?
- What should I avoid while taking tiludronate (Skelid)?
- What other drugs will affect tiludronate (Skelid)?
- Where can I get more information?
What should I discuss with my healthcare provider before taking tiludronate (Skelid)?
Do not take a tiludronate tablet if you cannot sit upright or stand for at least 30 minutes. Tiludronate can cause serious problems in the stomach or esophagus (the tube that connects your mouth and stomach). You will need to stay upright for at least 30 minutes after taking this medication.
To make sure you can safely take tiludronate, tell your doctor if you have any of these other conditions:
- a bone fracture;
- trouble swallowing;
- a stomach or esophageal ulcer or disease; or
- kidney disease.
Some people using medicines similar to tiludronate have developed bone loss in the jaw, also called osteonecrosis of the jaw. Symptoms may include jaw pain, swelling, numbness, loose teeth, gum infection, or slow healing after injury or surgery involving the gums.
You may be more likely to develop osteonecrosis of the jaw if you have cancer or have been treated with chemotherapy, radiation, or steroids. Other conditions associated with osteonecrosis of the jaw include blood clotting disorders, anemia (low red blood cells), and a pre-existing dental problem.
Talk with your doctor about the risks and benefits of using this medication.
FDA pregnancy category C. It is not known whether tiludronate will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication..
It is not known whether tiludronate passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.
How should I take tiludronate (Skelid)?
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
Do not crush, chew, or suck the pill. Swallow it whole.
Take each tiludronate tablet with a full glass (6 to 8 ounces) of water. Use only plain water (not mineral water) when taking a tiludronate tablet.
For at least the first 2 hours after taking tiludronate, do not eat or drink anything other than plain water, and do not take any other medicines including vitamins or mineral supplements.
Use tiludronate regularly to get the most benefit. Get your prescription refilled before you run out of medicine completely.
If you need to have any dental work (especially surgery), tell the dentist ahead of time that you are using tiludronate. You may need to stop using the medicine for a short time.
Your doctor will need to check your progress on a regular basis. Do not miss any scheduled appointments.
Tiludronate is only part of a complete program of treatment that may also include taking calcium and vitamin supplements. Follow your diet, medication, and exercise routines very closely.
Store at room temperature away from moisture and heat.
Additional Skelid Information
- Skelid Drug Interactions Center: tiludronate oral
- Skelid Side Effects Center
- Skelid Overview including Precautions
- Skelid FDA Approved Prescribing Information including Dosage
Skelid - User Reviews
Skelid User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Get tips and advances in treatment.